Aurobindo Pharma Limited Q2 FY27 results: what the company reported
Aurobindo Pharma Limited filed its unaudited financial results for the quarter ended 30 September 2026 (July to September 2026, called Q2 FY27) with NSE on 4 November 2026. The comparison below uses the company's signed filing, not a market-price report.
Published 7 November 2026 · Potoos Research Services
In short. For July to September 2026, Aurobindo Pharma Limited reported consolidated revenue from operations of Rs 1,02,632.9 million, compared with Rs 82,857.0 million a year earlier (+23.9%). Consolidated profit for the period was Rs 11,238.4 million, compared with Rs 8,481.3 million (+32.5%). For the company on its own (standalone), profit for the period was Rs 7,235.8 million, against Rs 5,813.7 million (+24.5%).
The numbers
The filing reports amounts in Rs million. One million rupees is ten lakh rupees. The EPS row is in rupees per share, not in the table's main unit. EPS is not annualised. The percentage columns have been calculated from the stated figures in the original filing. All year-on-year comparisons are against the same quarter or half-year last year, not the preceding quarter.
| Item | Jul to Sep 2026 | Jul to Sep 2025 | Year-on-year change |
|---|---|---|---|
| Revenue from operations | 1,02,632.9 | 82,857.0 | +23.9% |
| Total income | 1,04,315.1 | 84,062.9 | +24.1% |
| Profit before tax | 16,876.7 | 12,759.2 | +32.3% |
| Profit for the period | 11,238.4 | 8,481.3 | +32.5% |
| Basic EPS (Rs per share) | 19.57 | 14.61 | +33.9% |
| Item | Apr to Sep 2026 | Apr to Sep 2025 | Year-on-year change |
|---|---|---|---|
| Revenue from operations | 1,94,136.4 | 1,61,538.4 | +20.2% |
| Total income | 1,98,460.9 | 1,63,793.4 | +21.2% |
| Profit before tax | 32,027.7 | 24,827.2 | +29.0% |
| Profit for the period | 21,558.8 | 16,723.3 | +28.9% |
| Basic EPS (Rs per share) | 37.52 | 28.81 | +30.2% |
Compared with the immediately preceding April to June 2026 quarter (quarter-on-quarter), consolidated revenue from operations moved from Rs 91,503.5 million to Rs 1,02,632.9 million (+12.2%). Profit for the period moved from Rs 10,320.3 million to Rs 11,238.4 million (+8.9%). This is a different comparison from the previous-year column.
Aurobindo Pharma Limited on its own (standalone)
Standalone results cover Aurobindo Pharma Limited itself, without adding the subsidiaries and other group entities included in the consolidated figures. The statement uses the same Rs million unit.
| Item | Jul to Sep 2026 | Jul to Sep 2025 | Year-on-year change |
|---|---|---|---|
| Revenue from operations | 31,773.3 | 27,299.3 | +16.4% |
| Total income | 32,801.3 | 28,894.5 | +13.5% |
| Profit before tax (continuing operations) | 9,709.5 | 7,564.1 | +28.4% |
| Profit for the period | 7,235.8 | 5,813.7 | +24.5% |
| Basic EPS (Rs per share) | 12.58 | 10.01 | +25.7% |
| Item | Apr to Sep 2026 | Apr to Sep 2025 | Year-on-year change |
|---|---|---|---|
| Revenue from operations | 59,768.4 | 55,267.6 | +8.1% |
| Total income | 63,215.3 | 57,700.5 | +9.6% |
| Profit before tax (continuing operations) | 19,790.3 | 15,088.2 | +31.2% |
| Profit for the period | 14,608.0 | 11,405.0 | +28.1% |
| Basic EPS (Rs per share) | 25.33 | 19.64 | +29.0% |
Against April to June 2026 (quarter-on-quarter), standalone revenue from operations changed +13.5% from Rs 27,995.1 million to Rs 31,773.3 million. Standalone profit changed -1.9% from Rs 7,372.2 million to Rs 7,235.8 million.
What the company said
These points come from the company's own filing with NSE: the results, the notes to them and the board meeting letter. They are not our forecasts.
- On 29 June 2026, Aurobindo, through its US subsidiary Aurobindo Pharma USA, Inc., completed the purchase of 100% of Lannett Company LLC and its subsidiaries for Rs 23,218.3 million (USD 245.7 million). Lannett is included in the group figures from that date. The company says: "the results for the quarter and half year ended September 30, 2026, are not comparable to the earlier periods presented." (NSE filing, PDF p11)
- The group had no exceptional item in July to September 2026. April to June 2026 carried an exceptional expense of Rs 401.8 million, the costs of the Lannett purchase, so it sits inside the half-year figures, not this quarter. (NSE filing, PDF p8 and 12)
- From 1 April 2026 the company moved its Indian branded-medicines business to a wholly owned subsidiary, Auropharm Limited. In the standalone results that business is shown as a discontinued operation, and last year's standalone figures were re-presented on the same basis. The standalone profit before tax rows above are for continuing operations; standalone profit for the period includes a Rs 8.7 million loss from the discontinued business in July to September 2025. (NSE filing, PDF p3 and 6)
- The company bought back and cancelled 54,23,728 of its own shares (0.93% of the total) under a buyback approved on 6 April 2026, so EPS is now worked out on fewer shares. (NSE filing, PDF p12)
- The board declared an interim dividend of Rs 7 per share (face value Re 1), with 11 November 2026 as the record date, to be paid on or before 20 November 2026. (NSE filing, PDF p1)
Group profit attributable to Aurobindo's own shareholders was Rs 11,260.8 million, against Rs 8,484.5 million a year earlier (+32.7%); EPS is worked out on this figure. Because Lannett joined the group at the end of June 2026, the year-on-year changes compare a larger group with a smaller one.
What the auditors said
The figures are unaudited. The statutory auditors, Deloitte (Chartered Accountants), carried out a limited review of the standalone and consolidated results. A limited review is lighter than a full audit. The consolidated review report notes that some subsidiaries were reviewed by other auditors.
Dates
- Reporting period: 1 July to 30 September 2026 (Q2 FY27).
- Board meeting: 4 November 2026, from 16:15 to 18:00 IST.
- Filed with NSE: 4 November 2026 at 19:53 IST.
- Dividend: interim Rs 7 per share, record date 11 November 2026 (NSE filing, PDF p1).
Reported unit: The filing reports amounts in Rs million. One million rupees is ten lakh rupees. The EPS row is in rupees per share, not in the table's main unit. EPS is not annualised.
Consolidated and standalone: consolidated results describe the group, while standalone results describe the listed company itself. Where only standalone results were included in the reviewed PDF, no consolidated results have been invented.
Profit before tax and profit for the period: profit before tax is stated before the tax expense shown in the results. Profit for the period is after the relevant taxes. It is not the same as sales or revenue.
EPS: earnings per share, stated in rupees per equity share. In group accounts, EPS generally uses the part of profit attributable to owners of the parent, not the total group profit that may include minority shareholders.
Q2 FY27: the second quarter of the financial year that runs from April 2026 to March 2027. Year-on-year compares with the same period in 2025. Quarter-on-quarter compares with April to June 2026.
Source
- Aurobindo Pharma Limited, board meeting outcome with unaudited financial results filed 4 November 2026, 19:53 IST. Read the original NSE PDF.
This page was written by Potoos Research Services, a SEBI-registered Research Analyst (INH000027380) in Chennai. The financial figures above are transcribed from the original company filing, and each percentage is calculated from that filing's figures.
This page reports what the company filed. It is not a recommendation to buy, sell or hold.
Common questions
What was Aurobindo Pharma Limited's revenue in Q2 FY27?
Consolidated revenue from operations was Rs 1,02,632.9 million for July to September 2026 against Rs 82,857.0 million a year earlier, a year-on-year change of +23.9%.
Did Aurobindo Pharma Limited's Q2 FY27 profit rise or fall?
Consolidated profit for the period rose to Rs 11,238.4 million from Rs 8,481.3 million, a year-on-year change of +32.5%. Compared with April to June 2026, the change was +8.9%.
What does the reported unit mean?
One million rupees equals ten lakh rupees. Figures on this page are kept in Rs million, matching the filing.
Is this page a recommendation?
No. It reports the company's published financial results and is not a recommendation to buy, sell or hold securities.